Mabley, J.G., Rabinovitch, A., Suarez-Pinzon, W., et al. (2003) Inosine protects against the development of diabetes in multiple-low-dose streptozotocin and nonobese diabetic mouse models of type 1 diabetes. Molecular Medicine, 9, 96-104. http://dx.doi.org/10.2119/2003-00016.Mabley

has been cited by the following article:

• TITLE: Purine nucleotides and their metabolites in patients with type 1 and 2 diabetes mellitus

  AUTHORS: Wioleta Dudzinska

  KEYWORDS: Purine Nucleotides; Nucleosides; Purine Bases; Diabetes

  JOURNAL NAME: Journal of Biomedical Science and Engineering, Vol.7 No.1, January 24, 2014

  ABSTRACT: We measured the erythrocyte levels of principal nucleotides (ATP, ADP, AMP, GTP, GDP, GMP, IMP), nucleosides (Ado, Guo, Ino) and Hyp with HPLC. Purine concentrations were determined in the erythrocytes of 36 type 1 and 40 type 2 diabetic patients. The increased dephosphorylation of adenine and guanine nucleotides, indicated by increased Ado, Ino, Guo and Hyp concentrations as the products of purine nucleotide degradation, suggests serious energy metabolism disruptions in diabetes. An increase in AMP, GMP, IMP concentrations, as well as a decrease in AEC and GEC values, points to significant alterations in erythrocyte purine nucleotide concentration.